Patents by Inventor Pascal Gauduchon

Pascal Gauduchon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
    Publication number: 20130237584
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 12, 2013
    Applicant: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER - CENTRE FRANCOIS BACLESSE
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • Cancer therapy using Bcl-X-specific siNA
    Patent number: 8193333
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: June 5, 2012
    Assignee: Centre Regional de Lutte Contre le Cancer-Centre Francois Baclesse
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • CANCER THERAPY USING BCL-XL-SPECIFIC SINA
    Publication number: 20090312393
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 17, 2009
    Applicant: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER - CENTRE FRANCOIS BACLESSE
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras